Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE phase II trial of nivolumab + ipilimumab in molecularly selected metastatic castration-resistant prostate cancer
NL-OMON59921Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in castration-resistant prostate cancer (CRPC), sponsored by Radboud University Medical Center. Started Feb 2025; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON59921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59921.